Mindray to Report Fourth Quarter and Full Year 2010 Financial Results on February 28, 2011
{window.open('https://sns.qzone.qq.com/cgi-bin/qzshare/cgi_qzshare_onekey?url='+encodeURIComponent(location.href)+'&title='+encodeURIComponent(document.title)+'&summary=&desc=&pics=https://static.prnasia.com/pro/pcom/includes/images/logo-prn-02_PRN.png','_blank','width=650,height=450');})()){kind=link}
SHENZHEN, China, Feb. 11, 2011 /PRNewswire-Asia/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that it will report its financial results for the fourth quarter ended December 31, 2010 after the U.S. market closes on February 28, 2011. Mindray's management will hold an earnings conference call at 8:00 AM on March 1, 2011 U.S. Eastern Time (9:00 PM on March 1, 2011 Beijing/Hong Kong Time).
Dial-in details for the earnings conference call are as follows:
|
Hong Kong: |
+852-3002-1672 |
|
|
U.S. Toll Free: |
+1-866-788-0538 |
|
|
International: |
+1-857-350-1676 |
|
|
Passcode for all regions: |
Mindray |
|
|
U.S. Toll Free: |
+1-888-286-8010 |
|
|
International: |
+1-617-801-6888 |
|
|
Passcode: |
6529 4305 |
|
About Mindray
We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China and through our worldwide distribution network, we are able to supply internationally a broad range of products across three primary business segments, comprised of patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. For more information, please visit http://www.mindray.com.
|
For investor and media inquiries please contact: |
|
|
In the U.S.: |
|
|
In China: |
Related stocks: NYSE:MR
Featured Video
Recent Releases
- Mindray Announces Completion of Going Private Transaction
- Mindray Announces Shareholders' Approval of Merger Agreement
- Mindray Announces Extraordinary General Meeting of Shareholders
- Mindray Announced Shareholder Resolutions Post 2015 Annual General Meeting
- Mindray to Hold Annual General Meeting in Hong Kong on December 28, 2015
- Mindray Announces Settlement of Previously Described Masimo Related Litigation
- Go to MediaRoom
Health Care/Hospital Recent Releases
- Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
- CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
- Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
- Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
- Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
- Read more
Medical Equipment Recent Releases
- Neurophet to participate BIO USA… exploring global partnership and business
- Vieworks Showcases Innovative X-ray Imaging Solutions at WCNDT (World Conference on Non-Destructive Testing) 2024
- Oy Apotti Ab Partners with uPerform to Enhance EHR Education and Support
- One in Six Globally Concerned About Colorectal Cancer Screening Costs
- "Disrupt" introduces Disrupt Health Impact Fund with leading business groups in Thailand to invest in HealthTech startups globally
- Read more